AIM： To investigate the relationship between insulin resistance （IR）/β-cell dysfunction and diabetic retinopathy （DR） in Chinese patients with type 2 diabetes mellitus （T2DM）, and to explore further whether th...AIM： To investigate the relationship between insulin resistance （IR）/β-cell dysfunction and diabetic retinopathy （DR） in Chinese patients with type 2 diabetes mellitus （T2DM）, and to explore further whether there were differences in the relationship among diabetic patients with higher and lower body mass index （BMI）. METHODS： Cross-sectional study. A total of 1466 subjects with T2DM were recruited in a local Desheng Community of urban Beijing from November 2009 to June 2012 for the cohort of Beijing Desheng Diabetic Eye Study. Standardized evaluation was carried out for each participant, including questionnaire, ocular and anthropometric examinations, and laboratory tests. Seven fields 30° color fundus photographs were used for DR grading according to the Early Treatment Diabetic Retinopathy Study protocols. Homeostatis Model Assessment （HOMA） method was employed for IR and β-cell function assessment. RESULTS： After excluding those participants who were treated with insulin （n=352） or had missing data of fasting insulin （n=96）, and further excluding those with poor quality of retinal photographs （n=10）, a total of 1008 subjects were included for the final analysis, 406 （40.3%） were men and 602 （59.7%） were women, age ranging fiom 34 to 86 （64.87±8.28）y. Any DR （levels 14 and above） was present in 278 （27.6%） subjects. After adjusting for possible covariates, the presence of any DR did not correlate with HOMA IR [odds ratio （OR） 1.51, 95% confidence interval （Cl） 0.87-2.61, P=0.14] or HOMA β-cell （OR 0.71, 95%CI 0.40-1.26, P=0.25）. After stratification by BMI, the presence of any DR was associated positively with HOMA IR （OR 2.46, 95%CI： 1.18-5.12, P=0.016）, and negatively with HOMA β-cell （OR 0.40, 95%CI： 0.19-0.87, P=0.021） in the group of patients with higher BMI （225 kg/m2）. In the group of patients with lower BMI （〈25 kg/m2）, the presence of any DR was not associated with HOMA IR （OR 1.00, 95%C1： 0.43-2.33, P=I.00） or HOMA β-cell （OR 1.41, 95%CI： 0.60-3.32, P=0.43）. CONCLUSION： The data suggest that higher IR and lower 13-cell function are associated with the presence of DR in the subgroup of diabetic patients with higher BMI. However, this association is not statistically significant in diabetic patients with lower BMI.展开更多
目的观察应用利格列汀联合门冬胰岛素50治疗肝源性糖尿病患者的疗效及胰岛素抵抗指数(HOMAIR)和胰岛β细胞功能指数(HOMA-β)水平的变化。方法2017年1月~2019年12月我院收治的98例非酒精性脂肪性肝病合并肝源性糖尿病患者被随机分为对照...目的观察应用利格列汀联合门冬胰岛素50治疗肝源性糖尿病患者的疗效及胰岛素抵抗指数(HOMAIR)和胰岛β细胞功能指数(HOMA-β)水平的变化。方法2017年1月~2019年12月我院收治的98例非酒精性脂肪性肝病合并肝源性糖尿病患者被随机分为对照组49例和观察组49例,分别给予门冬胰岛素50或门冬胰岛素50联合利格列汀治疗,两组均治疗观察12 w。使用血糖仪检测空腹血糖(FBG)和餐后2 h血糖(2 h PG)水平,采用胶体金法检测血清糖化血红蛋白(HbAlc)水平,并计算HOMA-IR和HOMA-β,使用全自动生化分析仪检测血清肝功能指标。结果在治疗后,观察组FPG水平为(6.3±3.9)mmol/L,显著低于对照组【(7.8±1.2)mmol/L,P<0.05】,2 h PG水平为(8.4±2.6)mmol/L,显著低于对照组【(11.5±2.8)mmol/L,P<0.05】,和HbAlc水平为(7.1±1.6)%,显著低于对照组【(8.3±1.9)%,P<0.05】;治疗后,观察组HOMA-IR为(1.5±0.2),显著低于对照组【(2.4±03),P<0.05】,而HOMA-β水平为(42.9±8.7),显著高于对照组【(33.5±7.2),P<0.05】;观察组血清谷丙转氨酶(ALT)水平为(53.9±13.7)U/L,显著低于对照组【(72.2±19.6)U/L,P<0.05】,谷草转氨酶(AST)水平为(22.1±6.3)U/L,显著低于对照组【(46.4±6.9)U/L,P<0.05】,两组谷氨酰转肽酶、总胆红素和白蛋白水平无显著变化(P>0.05)。结论应用利格列汀联合门冬胰岛素50治疗非酒精性脂肪性肝病合并肝源性糖尿病患者能显著改善血糖水平,有效降低HOMA-IR,升高HOMA-β,改善了胰岛β细胞功能,从而改善患者的肝功能,具有良好的治疗效果。展开更多
基金Supported by the Beijing Natural Science Foundation(No.7131007)National Basic Research Program of China(973 ProgramNo.2007CB512201)
文摘AIM： To investigate the relationship between insulin resistance （IR）/β-cell dysfunction and diabetic retinopathy （DR） in Chinese patients with type 2 diabetes mellitus （T2DM）, and to explore further whether there were differences in the relationship among diabetic patients with higher and lower body mass index （BMI）. METHODS： Cross-sectional study. A total of 1466 subjects with T2DM were recruited in a local Desheng Community of urban Beijing from November 2009 to June 2012 for the cohort of Beijing Desheng Diabetic Eye Study. Standardized evaluation was carried out for each participant, including questionnaire, ocular and anthropometric examinations, and laboratory tests. Seven fields 30° color fundus photographs were used for DR grading according to the Early Treatment Diabetic Retinopathy Study protocols. Homeostatis Model Assessment （HOMA） method was employed for IR and β-cell function assessment. RESULTS： After excluding those participants who were treated with insulin （n=352） or had missing data of fasting insulin （n=96）, and further excluding those with poor quality of retinal photographs （n=10）, a total of 1008 subjects were included for the final analysis, 406 （40.3%） were men and 602 （59.7%） were women, age ranging fiom 34 to 86 （64.87±8.28）y. Any DR （levels 14 and above） was present in 278 （27.6%） subjects. After adjusting for possible covariates, the presence of any DR did not correlate with HOMA IR [odds ratio （OR） 1.51, 95% confidence interval （Cl） 0.87-2.61, P=0.14] or HOMA β-cell （OR 0.71, 95%CI 0.40-1.26, P=0.25）. After stratification by BMI, the presence of any DR was associated positively with HOMA IR （OR 2.46, 95%CI： 1.18-5.12, P=0.016）, and negatively with HOMA β-cell （OR 0.40, 95%CI： 0.19-0.87, P=0.021） in the group of patients with higher BMI （225 kg/m2）. In the group of patients with lower BMI （〈25 kg/m2）, the presence of any DR was not associated with HOMA IR （OR 1.00, 95%C1： 0.43-2.33, P=I.00） or HOMA β-cell （OR 1.41, 95%CI： 0.60-3.32, P=0.43）. CONCLUSION： The data suggest that higher IR and lower 13-cell function are associated with the presence of DR in the subgroup of diabetic patients with higher BMI. However, this association is not statistically significant in diabetic patients with lower BMI.
文摘目的观察应用利格列汀联合门冬胰岛素50治疗肝源性糖尿病患者的疗效及胰岛素抵抗指数(HOMAIR)和胰岛β细胞功能指数(HOMA-β)水平的变化。方法2017年1月~2019年12月我院收治的98例非酒精性脂肪性肝病合并肝源性糖尿病患者被随机分为对照组49例和观察组49例,分别给予门冬胰岛素50或门冬胰岛素50联合利格列汀治疗,两组均治疗观察12 w。使用血糖仪检测空腹血糖(FBG)和餐后2 h血糖(2 h PG)水平,采用胶体金法检测血清糖化血红蛋白(HbAlc)水平,并计算HOMA-IR和HOMA-β,使用全自动生化分析仪检测血清肝功能指标。结果在治疗后,观察组FPG水平为(6.3±3.9)mmol/L,显著低于对照组【(7.8±1.2)mmol/L,P<0.05】,2 h PG水平为(8.4±2.6)mmol/L,显著低于对照组【(11.5±2.8)mmol/L,P<0.05】,和HbAlc水平为(7.1±1.6)%,显著低于对照组【(8.3±1.9)%,P<0.05】;治疗后,观察组HOMA-IR为(1.5±0.2),显著低于对照组【(2.4±03),P<0.05】,而HOMA-β水平为(42.9±8.7),显著高于对照组【(33.5±7.2),P<0.05】;观察组血清谷丙转氨酶(ALT)水平为(53.9±13.7)U/L,显著低于对照组【(72.2±19.6)U/L,P<0.05】,谷草转氨酶(AST)水平为(22.1±6.3)U/L,显著低于对照组【(46.4±6.9)U/L,P<0.05】,两组谷氨酰转肽酶、总胆红素和白蛋白水平无显著变化(P>0.05)。结论应用利格列汀联合门冬胰岛素50治疗非酒精性脂肪性肝病合并肝源性糖尿病患者能显著改善血糖水平,有效降低HOMA-IR,升高HOMA-β,改善了胰岛β细胞功能,从而改善患者的肝功能,具有良好的治疗效果。
